| 摘要: |
| 目的：应用微小RNA（miRNA）基因表达谱芯片技术筛查miRNA在高脂血症及脉康汤治疗前后患者血浆中的差异表达，旨在进一步探索脉康汤治疗高脂血症的分子机制。方法：在本院中西医结合门诊筛选出符合中西医诊断标准的患者10 例，选择同年龄段正常人10 例，测定受试者血压、血糖、血脂和体质量指数（BMI），分别抽取外周血，常规提取总RNA，作miRNA芯片。取10 例患者中经脉康汤口服治疗显效的典型病例1 例，治疗前后分别抽取外周血，提取总RNA，作miRNA芯片检测miRNA表达谱。对差异表达的miRNA进行实时荧光定量聚合酶链反应（qRT-PCR）验证。结果：高脂血症患者与正常人的miRNA芯片差异表达谱与脉康汤治疗显效的典型病例治疗前后的miRNA芯片差异表达谱中有11条miRNA差异表达一致，其中有7个miRNA（miR-122、 miR-146a、miR-125a-5p、miR-208b、miR-370、miR-197、miR-365）上调，4个miRNA（miR-33a、miR-182-5p、miR-103、miR-542）下调，与qRT-PCR结果基本相符。结论：高脂血症患者血浆中miRNA的表达有明显改变，经脉康汤治疗后也随之向相反方向改变，提示血浆miRNA可作为预测脉康汤降脂预后的新型生物学标志物。 |
| 关键词: 高脂血症 脉康汤 miRNA 基因表达谱 生物学标志物 |
| DOI： |
|
|
| Effect of Maikang decoction on plasma microRNA expression profile of patients with hyperlipidemia |
| WANG Jia,WU Zhaoli |
| (Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University，Changsha 410016，Hunan，China) |
| Abstract: |
| Objective：To investigate the difference in the expression of microRNA （miRNA） before and after treatment with Maikang decoction in patients with hyperlipidemia using the miRNA gene expression microarray technique，and to further explore the molecular mechanism of Maikang decoction in the treatment of hyperlipidemia.Methods：A total of 10 patients who were screened out and met the diagnostic criteria based on traditional Chinese and Western medicine at the outpatient service of integrated traditional Chinese and Western medicine in our hospital were enrolled，and 10 normal individuals in the same age group were also enrolled.Blood pressure，blood glucose，blood lipids，and body mass index （BMI） were measured for all subjects；peripheral blood was collected to extract RNA and prepare miRNA microarray.Among the 10 patients，1 patient who achieved marked response after oral administration of Maikang decoction was selected，and peripheral blood was collected before and after treatment to extract RNA and prepare miRNA microarray to measure microRNA expression profile.Quantitative real-time PCR （qRT-PCR） was performed for differentially expressed miRNAs for validation.Results：The differential expression profile of miRNA microarray in hyperlipidemia patients and normal individuals were consistent with the differential expression profile of miRNA microarray in the typical case treated with Maikang decoction before and after treatment，and there were 11 differentially expressed miRNAs，among which 7 miRNAs （miR-122，miR-146a，miR-125a-5p，miR-208b，miR-370，miR-197，and miR-365） were upregulated and 4 miRNAs （miR-33a，miR-182-5p，miR-103，and miR-542） were downregulated，which was basically consistent with qRT-PCR results.Conclusion：There is a significant change in the expression of miRNAs in the plasma of patients with hyperlipidemia，with a change in the opposite direction after treatment with Maikang decoction，suggesting that plasma miRNA can be used as a new biomarker for predicting the prognosis after antihyperlipidemic treatment with Maikang decoction. |
| Key words: hyperlipidemia Maikang decoction microRNA gene expression profile biomarker |
